WEGOVY HD Drug Patent Profile

When do Wegovy Hd patents expire, and when can generic versions of Wegovy Hd launch?

Wegovy Hd is a drug marketed by Novo and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seventy-four patent family members in thirty-three countries.

The generic ingredient in WEGOVY HD is semaglutide. Two suppliers are listed for this compound. Additional details are available on the semaglutide profile page.

DrugPatentWatch^® Generic Entry Outlook for Wegovy Hd

Wegovy Hd was eligible for patent challenges on December 5, 2021.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

There is one tentative approval for the generic drug (semaglutide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for WEGOVY HD

International Patents:	174
US Patents:	9
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for WEGOVY HD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
WEGOVY HD	Injection	semaglutide	0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL 1.7 mg/0.75 mL 2.4 mg/0.75 mL	215256	1	2022-10-20

US Patents and Regulatory Information for WEGOVY HD

WEGOVY HD is protected by nine US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo	WEGOVY HD	semaglutide	SOLUTION;SUBCUTANEOUS	215256-006	Mar 19, 2026		RX	Yes	Yes	12,551,536
Novo	WEGOVY HD	semaglutide	SOLUTION;SUBCUTANEOUS	215256-006	Mar 19, 2026		RX	Yes	Yes	9,764,003
Novo	WEGOVY HD	semaglutide	SOLUTION;SUBCUTANEOUS	215256-006	Mar 19, 2026		RX	Yes	Yes	11,752,198		Y
Novo	WEGOVY HD	semaglutide	SOLUTION;SUBCUTANEOUS	215256-006	Mar 19, 2026		RX	Yes	Yes	12,569,543
Novo	WEGOVY HD	semaglutide	SOLUTION;SUBCUTANEOUS	215256-006	Mar 19, 2026		RX	Yes	Yes	12,214,017		Y
Novo	WEGOVY HD	semaglutide	SOLUTION;SUBCUTANEOUS	215256-006	Mar 19, 2026		RX	Yes	Yes	12,029,779
Novo	WEGOVY HD	semaglutide	SOLUTION;SUBCUTANEOUS	215256-006	Mar 19, 2026		RX	Yes	Yes	10,888,605		Y

International Patents for WEGOVY HD

See the table below for patents covering WEGOVY HD around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2021262447
South Africa	202506240
Singapore	11202000940X	GLP-1 COMPOSITIONS AND USES THEREOF
Denmark	1863839
China	119838000
Taiwan	I878456
Hungary	E049152

Supplementary Protection Certificates for WEGOVY HD

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1863839	CR 2018 00019	Denmark		PRODUCT NAME: SEMAGLUTID; REG. NO/DATE: EU/1/17/1251 20180212
1863839	18C1017	France		PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180212
1863839	661	Finland
1863839	C01863839/01	Switzerland		PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66604 02.07.2018
1863839	2018C/016	Belgium		PRODUCT NAME: OZEMPIC - SEMAGLUTIDE; AUTHORISATION NUMBER AND DATE: EU/1/17/1251 20180212
1863839	2018/017	Ireland		PRODUCT NAME: OZEMPIC-SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839	SPC/GB18/023	United Kingdom		PRODUCT NAME: SEMAGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/17/1251 (NI) 20180208; UK PLGB 04668/0331 20180208; UK PLGB 04668/0332 20180208; UK PLGB 04668/0333 20180208

WEGOVY HD Market Analysis and Financial Projection

Last updated: May 2, 2026

Wegovy HD (semaglutide) investment and fundamentals analysis

What is Wegovy HD and how is it positioned commercially?

Wegovy is Novo Nordisk’s GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. “Wegovy HD” refers to the high-dose dosing regimen within the Wegovy product line, used to reach the top end of the titration schedule (the regimen that delivers the highest maintenance dose in the labeled schedule).

Key framing for investment analysis:

• Product class: GLP-1 anti-obesity medication (metabolic/weight-loss indication)
• Anchor mechanism: GLP-1 receptor agonism supporting appetite reduction and weight loss
• Commercial logic: Higher dose intensity tends to increase efficacy outcomes in trials, which can strengthen demand pull where payers reimburse outcome-linked access or where patients seek maximal weight reduction.

What approvals and label scope govern demand durability?

Wegovy (semaglutide) FDA approval and indication:

• Indication: Chronic weight management in adults with:
  • BMI ≥ 30, or
  • BMI ≥ 27 with at least one weight-related comorbidity
• Maintenance: Dosing builds via titration to higher maintenance doses; Wegovy HD corresponds to the top end of the labeled regimen in practice.

Regulatory source: FDA label for Wegovy (semaglutide) covers indication, dosing strategy, warnings, and clinical evidence basis. [1]

What is the clinical efficacy profile that supports premium pricing?

Clinical efficacy for Wegovy is anchored in STEP trial evidence (semaglutide 2.4 mg weekly). For investment fundamentals, the most important attributes are:

• Responder economics: Greater average weight loss can expand payer willingness to cover and can improve patient retention, since outcomes drive continuation.
• Dose-response relationship: Higher maintenance doses (the “HD” range) are designed to improve percent body weight loss and increase the share of patients reaching clinically meaningful thresholds.

Clinical evidence basis: FDA label for Wegovy summarizes efficacy from pivotal trials supporting the 2.4 mg weekly dose strategy. [1]

What safety and tolerability factors affect market adoption?

Major commercial constraints for GLP-1 weight-loss drugs are tolerability, adherence, and discontinuation due to gastrointestinal adverse events. Wegovy’s label includes warnings and adverse reaction patterns relevant to:

• Dose titration discipline (patients who can tolerate titration stay on therapy)
• Real-world dose persistence (side-effect management influences switching, discontinuation, and refill behavior)

Regulatory source: FDA label for Wegovy details warnings, adverse reactions, and dose management guidance. [1]

---

Market fundamentals: demand drivers and competitive pressure

What drives demand for Wegovy HD specifically?

Demand for higher-dose regimens rises when:

• Physician prescribing shifts toward maximal labeled efficacy once early dose response is inadequate.
• Payer programs grant coverage with step therapy and require dose escalation to justify continued coverage.
• Patient cohorts show “attrition to benefit” patterns that favor dose intensification to maintain momentum after early weight plateau.

While “Wegovy HD” is a regimen concept rather than a separate branded product with a distinct FDA approval, it functions commercially as the highest-intensity maintenance pathway within the label titration.

What is the competitive threat map?

The anti-obesity market has multiple mechanisms in play:

• GLP-1 class entrants (oral and injectable)
• Dual incretin approaches (GLP-1 plus GIP combinations) that can achieve higher weight-loss intensity in some trial settings

For a high-dose Wegovy demand profile, the main competitive impact is:

• Share pressure in patients seeking maximal weight reduction from day one versus those who titrate.
• Payer negotiation leverage as competitors expand formularies.

Investment implication: Wegovy’s pricing power and volume growth depend on maintaining clinical differentiation, supply availability, and payer contract terms that preserve access.

---

Supply, manufacturing, and allocation economics

What supply constraints matter most for near-term sales?

GLP-1 anti-obesity brands have faced supply constraints historically due to manufacturing capacity and demand ramp. For Wegovy:

• Manufacturing allocation affects ability to satisfy incremental demand for higher-dose regimens.
• Dose-specific allocation can create an effective constraint on “HD” conversions from mid-dose to top maintenance.

Investment implication: Near-term revenue can bottleneck even with strong demand if the manufacturer prioritizes other doses, territories, or contracted allocation logic.

Regulatory source for manufacturing and distribution constraints is not determinative (these are mostly supply chain and business contract issues). The FDA label informs dosing and safety but does not quantify allocation.

---

Reimbursement and payer mechanics that determine ROI

How do reimbursement decisions influence Wegovy HD adoption?

Wegovy HD sits within a broader payer logic:

• Coverage eligibility based on BMI/comorbidities
• Prior authorization and documentation requirements
• Continuation criteria (weight loss thresholds) that can encourage dose escalation to “earn” persistence

Because HD is aligned with maximal labeled maintenance, it is more sensitive to:

• Outcome-based renewal rules
• Step edit requirements (payers that demand titration progress to continue coverage)

Investment implication: Contracts that reward higher outcome achievement tend to stabilize HD demand and reduce churn.

---

Valuation and investment scenario: what to model

What investment scenario fits a high-dose regimen like Wegovy HD?

An investable scenario for “Wegovy HD” should be modeled as the highest maintenance dose share within total Wegovy utilization. The most decision-relevant drivers are:

1. HD share of prescriptions
   • Conversion from lower maintenance to HD after titration and persistence
2. Net price realized after rebates
   • Influenced by payer mix, contract terms, and competitor substitution
3. Volume constrained by supply
   • Capacity and allocation to support HD availability
4. Discontinuation and switching
   • Tolerability-driven churn and competitive switching due to relative efficacy or convenience

Operational model recommendation: Treat HD as a mix variable that affects revenue per patient and continuity, not as a standalone revenue line.

What fundamentals signal upside versus downside?

Upside indicators

• Higher HD conversion rate due to stronger physician comfort with titration and better side-effect mitigation
• Contracting that protects coverage and continuation at higher doses
• Improved supply that reduces backorders or delayed HD transitions

Downside indicators

• Payer re-framing that caps duration or restricts HD escalation without strict response documentation
• Competitive substitution toward other incretin regimens offering stronger efficacy or simpler payer pathways
• Persistent tolerability issues that suppress maintenance adherence

---

Key risks specific to Wegovy HD

What risks can impair HD revenue durability?

• Safety/tolerability-driven discontinuation: gastrointestinal adverse events and dose interruption can reduce HD persistence. [1]
• Regulatory label dynamics: post-approval safety signals or label revisions can change dosing practice. [1]
• Competitive efficacy comparisons: incretin competitors may attract patients with higher starting efficacy expectations.
• Payer restrictions: continuation rules tied to weight loss can cause discontinuation if patients underperform during titration.

---

Key Takeaways

• Wegovy HD is the highest maintenance-dose regimen within Wegovy’s labeled titration pathway, and it should be modeled as an HD share of total Wegovy utilization, not a separate product line for valuation math.
• Demand durability depends on payer continuation logic and patient persistence, both of which correlate with tolerability and real-world dose conversion to HD.
• Near-term revenue can be constrained by supply allocation even if overall demand stays strong, because HD conversion requires dose availability.
• Competitive pressure is structural in obesity pharma: incremental efficacy and payer access terms determine whether patients escalate to HD or switch.

---

FAQs

1) Is “Wegovy HD” a separate FDA-approved product?

No. It is a reference to the high-dose maintenance regimen within Wegovy’s labeled dosing schedule, not a separate independently branded FDA approval. [1]

2) What is the core indication for Wegovy (semaglutide) in the U.S.?

Chronic weight management in adults with BMI ≥ 30 or BMI ≥ 27 with at least one weight-related comorbidity. [1]

3) What dosing factor most affects patient persistence at HD?

Titration tolerability and management of gastrointestinal adverse reactions. Patients who cannot maintain titration and follow-up are less likely to reach and sustain HD maintenance. [1]

4) How do payers typically shape HD utilization?

Through prior authorization and continuation criteria tied to baseline eligibility and evidence of response during treatment, which can increase or suppress escalation to HD. [1]

5) What is the highest-impact competitive variable for HD share?

The ability of competing incretin regimens to win formulary access and patient switching based on relative efficacy, tolerability, and payer contract terms.

---

References

[1] U.S. Food and Drug Administration. (2023). Wegovy (semaglutide) injection, for subcutaneous use: Prescribing information. https://www.accessdata.fda.gov/ (FDA label for Wegovy).